Morbidity

Percent prevalence of chronic conditions among users of chronic drugs program, 2016*

Chronic conditions	Prevalence
Cardiovascular diseases, atherosclerosis, coagulation problems and hypertension	47%
Diabetes	15%
Ulcers	10%
High cholesterol level	10%
Other diseases (Rheumatism, uric acid, glaucoma, osteoporosis...)	8%
Diseases of the nervous system	3%
Epilepsy	3%
Thyroid Problems	2%
Asthma	2%

*For previous years check the Statistical Bulletins' page

Newly reported HIV cases, 2020

Newly reported HIV cases,2021

Newly reported HIV cases, 2022

New reported HIV cases,2023

New reported HIV cases,2024

https://www.moph.gov.lb/userfiles/files/Prevention/TB%20Program/NTP-NAP%20Annual%20Report-2024.pdf

Number of Measles cases

	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Measles	9	1,760	235	39	44	126	952	1070	-	28	95	351

Source :MoPH 01/09/2024

Number of Tuberculosis cases*

Tuberculosis cases	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total number of cases	630	689	682	666	657	632	668	760	656	466	510	510	540
Number of Lebanese cases	330	341	337	312	305	271	254	288	277	233	263	249	225
Number of Non-Lebanese cases	300	348	345	354	352	361	414	472	379	233	247	261	315

*MOPH National Tuberculosis Program 01/05/2025

The trend in Tuberculosis cases by Nationality between 2019 and 2024

All

ATC	Name	B/G ↑	Ingredients	Dosage	Form	Price
G04BC	URALYT-U	B	Potassium Sodium Hydrogen Citrate - 2427.7mg	2427.7mg	Granules	1,351,906 L.L
G04BD02	URISPAS	B	Flavoxate HCl - 200mg	200mg	Tablet, film coated	1,094,272 L.L
N01AH06	ULTIVA	B	Remifentanil (HCl) - 5mg	5mg	Injectable powder for solution	2,990,050 L.L
N01AH06	ULTIVA	B	Remifentanil (HCl) - 2mg	2mg	Injectable powder for solution	1,632,769 L.L
V03AF01	UROMITEXAN	B	Mesna - 400mg/4ml	400mg/4ml	Injectable solution	2,632,587 L.L
A07FA02	ULTRA LEVURE	B	Saccharomyces boulardii - 50mg	50mg	Capsule	381,651 L.L
A07FA02	ULTRA LEVURE	B	Saccharomyces boulardii - 200mg	200mg	Capsule	513,348 L.L
A07FA02	ULTRA LEVURE	B	Saccharomyces boulardii - 100mg	100mg	Powder for suspension	536,193 L.L
J07AX	URO-VAXOM	B	Lyophilized bacterial lysates of E-Coli - 6mg	6mg	Capsule	2,689,029 L.L
R03AL04	ULTIBRO BREEZHALER	B	Indacaterol - 110mcg, Glycopyronium - 50mcg		Capsule, inhalation	4,031,528 L.L
G03DA04	UTROGESTAN	B	Progesterone micronised natural - 100mg	100mg	Capsule	525,442 L.L
G03DA04	UTROGESTAN	B	Progesterone micronised natural - 100mg	100mg	Capsule	525,442 L.L
G03DA04	UTROGESTAN	B	Progesterone micronised natural - 100mg	100mg	Capsule	525,442 L.L
G03DA04	UTROGESTAN	B	Progesterone micronised natural - 200mg	200mg	Capsule	587,259 L.L
G03DA04	UTROGESTAN	B	Progesterone micronised natural - 200mg	200mg	Capsule	587,259 L.L
G03DA04	UTROGESTAN	B	Progesterone micronised natural - 200mg	200mg	Capsule	587,259 L.L
B01AC27	UPTRAVI	B	Selexipag - 200mcg	200mcg	Tablet, film coated	275,097,581 L.L
B01AC27	UPTRAVI	B	Selexipag - 200mcg	200mcg	Tablet, film coated	613,462,617 L.L
B01AC27	UPTRAVI	B	Selexipag - 400mcg	400mcg	Tablet, film coated	275,097,581 L.L
B01AC27	UPTRAVI	B	Selexipag - 600mcg	600mcg	Tablet, film coated	275,097,581 L.L
B01AC27	UPTRAVI	B	Selexipag - 800mcg	800mcg	Tablet, film coated	275,097,581 L.L
B01AC27	UPTRAVI	B	Selexipag - 1000mcg	1000mcg	Tablet, film coated	275,097,581 L.L
B01AC27	UPTRAVI	B	Selexipag - 1200mcg	1200mcg	Tablet, film coated	275,097,581 L.L
B01AC27	UPTRAVI	B	Selexipag - 1400mcg	1400mcg	Tablet, film coated	275,097,581 L.L
B01AC27	UPTRAVI	B	Selexipag - 1600mcg	1600mcg	Tablet, film coated	275,097,581 L.L
A05AA02	URSOFALK	B	Ursodeoxycholic acid - 250mg	250mg	Capsule	2,823,413 L.L
B05AA01	UMAN ALBUMIN	BioHuman	Albumin human - 20g/100ml	10g/50ml	Injectable solution	3,598,810 L.L
L04AC05	USTEKIREL	BioTech	Ustekinumab - 45mg	45mg	Injectable solution	62,284,555 L.L
L04AC05	USTEKIREL	BioTech	Ustekinumab - 90mg	90mg	Injectable solution	94,672,508 L.L
C02CA04	UNIPROST	G	Doxazosin - 4mg	4mg	Tablet	452,875 L.L